Zynerba Pharmaceuticals, Inc. ZYNE
Day range unavailable
52-week range unavailable
- Market cap
- 70.12M
- Shares out
- 53.94M
- Forward P/E
- -2.28
- Beta
- 1.19
- Analysts
- Hold
- Price target
- 1.25 (-3.8%)
- Earnings date
- Nov 13, 2023
Key statistics
- Enterprise value
- 29.85M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.79M
- Total cash
- 35.97M
- Total debt
- 217.88K
- Return on equity
- -87.13%
- Short % of float
- 0.83%
- 50-day average
- 1.21
- 200-day average
- 0.62141
Analyst view
Consensus: hold
- Target (low)
- 1.11
- Target (mean)
- 1.25
- Target (high)
- 1.40
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 13, 2023
Expected Nov 13, 2023. Consensus EPS estimate 0.19.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2023 | Sep 1, 2023 | -0.20 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.20 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.20 | — | — | — |
| Mar 28, 2023 | Dec 1, 2022 | -0.24 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.21 | — | — | — |
| Aug 10, 2022 | Jun 1, 2022 | -0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | Canaccord Genuity | down | Buy | Hold |
| Aug 14, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 22, 2022 | Canaccord Genuity | main | — | Buy |
| Jun 30, 2020 | Needham | down | Buy | Hold |
| May 27, 2020 | Cantor Fitzgerald | main | — | Overweight |
| Oct 20, 2019 | Needham | init | — | Buy |
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- zynerba.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ZYNE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANIDO ARMANDO | Chief Executive Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| COOPER WARREN D | Director | Sale | Jun 13, 2023 | 75,778 |
| FEDERICI WILLIAM J | Director | Sale | Jun 13, 2023 | 75,778 |
| FICKENSCHER JAMES E | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| JONES KENNETH T | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2023 | 0 |
| KISNER DANIEL L | Director | Sale | Jun 13, 2023 | 75,778 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.04% | 2,179,600 | 710.55K | Jun 29, 2023 |
| Blackrock Inc. | 1.37% | 740,524 | 241.41K | Jun 29, 2023 |
| ETF Managers Group, LLC | 1.34% | 723,151 | 310.95K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.28% | 689,713 | 224.85K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.72% | 387,346 | 126.27K | Jun 29, 2023 |
| Penserra Capital Management LLC | 0.41% | 220,858 | 72.00K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 1,521,801 | 496.11K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.12% | 604,155 | 196.95K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.44% | 238,972 | 79.82K | May 30, 2023 |
| Amplify Seymour Cannabis ETF | 0.41% | 220,858 | 80.61K | Jul 30, 2023 |
| Fidelity Total Market Index Fund | 0.10% | 56,274 | 18.80K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 52,200 | 17.02K | Jun 29, 2023 |